PMID-12782416 – DSIP Decreases Spontaneous Tumor Incidence in Mice
Anisimov VN, et al. "Effect of Deltaran on spontaneous carcinogenesis, life span and biomarkers of aging in female SHR mice." Bull Exp Biol Med. 2003;135(6):586-589.
Quick Reference
| Property | Value |
|---|---|
| PMID | 12782416 |
| DOI | — |
| Year | 2003 |
| Journal | Bulletin of Experimental Biology and Medicine |
| Study Type | Animal in vivo |
| Evidence Level | V (animal study) |
| Sample | Female SHR mice, lifetime study |
| Peptide(s) Studied | DSIP |
Key Findings
- Deltaran (DSIP preparation) decreased spontaneous tumor incidence 2.6-fold compared to controls
- Specific reductions observed in mammary carcinomas and leukemias
- Treatment was well tolerated with no apparent toxicity over the study duration
- DSIP is one of the few vault peptides with preclinical evidence suggesting anti-tumor properties
- Mechanism likely related to circadian/neuroendocrine normalization rather than direct cytotoxicity
Study Design
Lifetime carcinogenesis study in female SHR mice. Deltaran (a pharmaceutical preparation of DSIP) was administered and animals were followed for spontaneous tumor development, lifespan, and biomarkers of aging. Tumor incidence, type, and latency were compared between treated and control groups.
Limitations
- Single mouse strain (SHR) — generalizability unknown
- Mechanism of anti-tumor effect not fully characterized
- Animal model only; no human cancer prevention data for DSIP
- SHR mice have a naturally high spontaneous tumor incidence, which may amplify the observed effect
- Anisimov group specializes in anti-aging peptide research — independent replication warranted
Clinical Relevance
This study provides reassuring safety data for DSIP use in the context of cancer risk. Unlike many peptides in the vault that carry angiogenic or growth-promoting concerns (BPC-157, TB-500, GHK-Cu), DSIP appears to have a neutral-to-protective cancer profile. This makes DSIP a potentially reasonable option for sleep support in cancer patients or cancer survivors, with oncologist awareness. The anti-tumor effect may be mediated through circadian rhythm normalization and melatonin pathway support, consistent with the known relationship between sleep disruption and cancer risk.
Related
#research #animal-in-vivo #evidence-level-V #DSIP #cancer